XML 23 R14.htm IDEA: XBRL DOCUMENT
v3.22.1

INVESTMENTS – RELATED PARTIES | 3 Months Ended
--- | ---
Mar. 31, 2022
Investments Related Parties |
INVESTMENTS – RELATED PARTIES | 8. INVESTMENTS – RELATED PARTIES Investments in Alzamend and Ault & Company at March 31, 2022 and December 31, 2021, were comprised of the following: Investment in Promissory Notes, Related Parties
|  | Interest |  |  | Due |  |  | March 31, |  |  | December 31, |
|  | Rate |  |  | Date |  |  | 2022 |  |  | 2021 |
Investment in promissory note of Ault & Company |  |  | 8 | % |  |  | December 31, 2022 |  |  | $ | 2,500,000 |  |  | $ | 2,500,000 |
Accrued interest receivable, Ault & Company |  |  |  |  |  |  |  |  |  |  | 153,000 |  |  |  | 170,000 |
Other |  |  |  |  |  |  |  |  |  |  | - |  |  |  | 172,000 |
Total investment in promissory note, related party |  |  |  |  |  |  |  |  |  | $ | 2,653,000 |  |  | $ | 2,842,000 |
Investment in Common Stock and Options, Related Parties
|  | March 31, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
Investment in common stock and options of Alzamend |  | $ | 8,729,000 |  |  | $ | 13,230,000 |
The following table summarizes the changes in the Company’s investments in Alzamend and Ault & Company during the three months ended March 31, 2022:
|  | Investment in warrants and common stock of Alzamend |  |  | Investment in promissory notes and advances of Alzamend and Ault & Company and Other |
Balance at January 1, 2022 |  | $ | 13,230,000 |  |  | $ | 2,842,000 |
Investment in common stock and options of Alzamend |  |  | 194,000 |  |  |  | - |
Unrealized loss in common stock of Alzamend |  |  | (4,695,000 | ) |  |  | - |
Amortization of related party investment |  |  | - |  |  |  | (173,000 | )
Accrued interest |  |  | - |  |  |  | (16,000 | )
Balance at March 31, 2022 |  | $ | 8,729,000 |  |  | $ | 2,653,000 |
Investments in Alzamend Common Stock The following table summarizes the changes in the Company’s investments in Alzamend common stock during the three months ended March 31, 2022:
|  | Shares of |  |  | Per Share |  |  | Investment in |
|  | Common Stock |  |  | Price |  |  | Common Stock |
Balance at January 1, 2022 |  |  | 6,947,000 |  |  | $ | 1.90 |  |  | $ | 13,230,000 |
Open market purchases after initial public offering |  |  | 153,000 |  |  | $ | 1.27 |  |  |  | 194,000 |
Unrealized loss in common stock of Alzamend |  |  |  |  |  |  |  |  |  |  | (4,691,000 | )
Investment in Alzamend common stock |  |  | 7,100,000 |  |  | $ | 1.23 |  |  |  | 8,733,000 |
Investment in Alzamend options |  |  |  |  |  |  |  |  |  |  | (4,000 | )
Balance at March 31, 2022 |  |  |  |  |  |  |  |  |  | $ | 8,729,000 |

X
- References No definition available. + Details
Name: | dpw_DisclosureInvestmentsRelatedPartiesAbstract
Namespace Prefix: | dpw_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The element represents investments related parties disclosure text block. + References No definition available. + Details
Name: | dpw_InvestmentsRelatedPartiesDisclosureTextBlock
Namespace Prefix: | dpw_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration